Novelrad and the EIC Accelerator: Stitching Arteries From Inside

30 September 2026870 words5 min

Novelrad, based at Kibbutz Metzer in northern Israel, has developed what it calls a micro-sewing machine that places a multipoint, continuous running suture through a catheter, mimicking the surgical standard for closing holes in blood vessels and the heart. Its first product, the N-VCD, closes the large puncture in the artery left by large-bore catheter procedures, by placing a purse-string suture at the start of the procedure, according to Novelrad. The EIC Accelerator granted €2,499,999 towards a total cost of €4,121,069 for the project, which runs from August 2024 to January 2027, according to CORDIS.

The project's first report, covering August 2024 to May 2025, says Novelrad completed the design of the N-VCD, moved production to a class 7 clean room, completed 14 of 19 mechanical bench tests, and ran a preclinical validation study in 7 acute and 7 chronic animals, the first of which completed follow-up "with very good results", according to CORDIS. It said the company was preparing its first-in-human trial. That study is now registered: ClinicalTrials.gov record NCT07858903, first posted on 5 October 2026, lists a Novelrad-sponsored first-in-human study of initial safety and preliminary efficacy in 15 patients at three Israeli hospitals, started on 30 November 2025 and completed on 18 August 2026. No results were posted on the registry as of 7 November 2026.

€2.5MEIC grant
14Animals in preclinical validation
2Patents granted, Europe and Japan
15Patients in first human study

Company file

Legal entity
Novelrad Ltd, Kibbutz Metzer, Israel
First product
N-VCD large-bore vascular closure device
Second product
N-PFO, heart defect closure
Technology
Transcatheter continuous micro-suturing
Stage
First-in-human study completed Aug 2026, no results posted
Ownership
Privately held
EIC funding
€2.5M grant, blended finance scheme

Where Novelrad Stands Now

On 7 November 2026, the news shown on Novelrad's website covered only the EIC award, and the site says its products are not approved for clinical use. The project report lists biocompatibility, sterilisation and packaging validation steps under way in mid-2025 with outside test laboratories, and two patents granted in Europe and Japan, with others in national phases. Sources reviewed on 7 November 2026 do not disclose its investors, funding or staff numbers, and as an Israeli private company its accounts are not public.

The record

From Kibbutz Metzer to a first human study

Novelrad's EIC project runs until January 2027. A 15-patient first-in-human study in Israel ran from November 2025 to August 2026; no results were posted by 7 November 2026.

  1. Nov 2023EIC Accelerator cut-offNVCDblended finance scheme
  2. Aug 2024EIC project starts€2.5M EU contribution
  3. 2024-2025Clean room production lineClass 7
  4. By May 2025Preclinical study7 acute and 7 chronic animals
  5. By May 2025Patents grantedEurope and Japan
  6. Mid-2025First-in-human trial in preparationProject report
  7. Nov 2025First-in-human study starts15 patients, Israel
  8. Aug 2026First-in-human study completedNo results posted
  9. Jan 2027EIC project endsScheduled

CORDIS and ClinicalTrials.gov NCT07858903.

"With these fundamental achievements in hand, Novelrad is now preparing to initiate its First-In-Human (FIH) clinical trials."

Novelrad, EIC project report, 2025

The Technology: A Purse-String Stitch Through a Catheter

Large-bore catheter procedures leave a large hole in the artery, which must be closed at the end. Novelrad's device places a continuous purse-string suture around the access site at the beginning of the procedure, with what the company describes as a ballpoint-pen interface. The same suturing platform is meant to close heart defects such as a patent foramen ovale.

The preclinical study

Animals in the preclinical validation study

The validation study used 14 animals. Novelrad reported very good results for the first chronic animal to finish follow-up.

Novelrad, EIC project report on CORDIS.

What the EIC Award Promised, and What the Record Shows

The project runs until January 2027, so it is too early to judge it. The company reports a finished design, most of the bench testing and a preclinical study. The 15-patient first-in-human study is registered as completed, but no results were public on 7 November 2026, so whether the device works in patients is not yet shown.

  1. Design completionDeliveredProject report.
  2. Preclinical validationDelivered14 animals.
  3. Verification testing14 of 19May 2025.
  4. First-in-human trialNo resultsCompleted Aug 2026.

The Money

The EU contribution covers 61% of the €4.1 million project; the rest is other project costs. CORDIS lists the project under the EIC Accelerator blended finance scheme, but sources reviewed on 7 November 2026 show no EIC Fund investment or other funding round.

The testing

Mechanical bench tests completed by mid-2025

Novelrad had completed 14 of its 19 planned bench tests at the end of the first reporting period in May 2025.

Novelrad, EIC project report on CORDIS. Number of tests.

The EIC project

Who pays for NVCD

The EU contribution covers 61% of the €4.12 million project cost; the rest is other project costs.

CORDIS, project 101166562. Values in € thousands.

What Cannot Be Checked

Questions for the EIC

The results of the first-in-human study, who funds Novelrad and whether the EIC Fund will invest are not public.

Why Europe Should Care

Novelrad says its technology is designed to improve results, shorten procedures and reduce hospital stays. The EIC grant has paid for the engineering and animal work behind those claims, but the clinical evidence in patients is still to be generated.

What the award promised

Minimally invasive suturing for vascular closure and heart defect repair.

What the record shows

A finished design, animal data and a completed 15-patient human study with no published results.

The Verdict

First human study done, results not yet public

Novelrad reports finished engineering and has run a 15-patient first human study. Its results are not yet public.

Novelrad and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.

Industry

HealthMedical devices

Focus
  • Cardiovascular devices
Technologies
  • Catheter technology
Keywords
  • Vascular closure
  • Large-bore access
  • Structural heart procedures
  • Suturing